Yamashita Yoshio, Nakayama Yukishi, Goto Masaaki
Dept. of Oral and Maxillofacial Surgery, Saga Medical School.
Gan To Kagaku Ryoho. 2014 Jan;41(1):83-6.
We report the development of a prominent rash in response to alternate-day S-1 administration in a patient with oral cancer. The patient was a 75-year-old woman with left-side lower gingival cancer(T4N1M0). After chemoradiotherapy, the patient underwent radical surgery. She was treated with oral S-1, administered on alternate days at a dosage of 80mg/day (orally, twice per day), as postoperative adjuvant chemotherapy. Edematous erythema, accompanied by strong itching and paraesthesia, appeared focally on the face and the limbs 1 month after beginning S-1 treatment. Since the rash was determined to be drug-induced, S-1 administration was stopped, and steroid, antihistamine, and topical steroid treatment was initiated. The symptoms gradually improved, and the rash disappeared without recurrence approximately 1 month later. Although alternate-day administration is considered to be a safe and effective method to administer S-1 oral therapy, it should be noted that cutaneous symptoms might appear after a fixed dosage is exceeded.
我们报告了1例口腔癌患者在接受隔日S-1给药后出现明显皮疹的情况。该患者为75岁女性，患有左侧下牙龈癌（T4N1M0）。放化疗后，患者接受了根治性手术。术后辅助化疗给予口服S-1，隔日给药，剂量为80mg/天（口服，每日2次）。开始S-1治疗1个月后，面部和四肢局部出现水肿性红斑，伴有强烈瘙痒和感觉异常。由于皮疹被确定为药物性，停止S-1给药，并开始使用类固醇、抗组胺药和外用类固醇治疗。症状逐渐改善，皮疹在约1个月后消失，未复发。虽然隔日给药被认为是一种安全有效的S-1口服治疗方法，但应注意，超过固定剂量后可能会出现皮肤症状。
